Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“NLRP3 Inhibition in Atherosclerosis: Early Clinical Signal Beyond Lipids
Targeting residual inflammatory risk has become a central challenge in contemporary cardiovascular prevention, particularly in patients who achieve optimal LDL-C control yet remain at elevated risk.
Within this framework, the NLRP3 inflammasome has emerged as a pivotal upstream regulator of vascular inflammation, orchestrating the IL-1B-IL-6-CRP signaling cascade that drives plaque progression, instability, and eventual clinical events.
Early clinical evidence with the oral NLRP3 inhibitor VTX3232 provides a compelling proof-of-concept for this therapeutic strategy.
In a randomized, double-blind phase 2a trial involving individuals with obesity and heightened cardiometabolic risk, treatment with VTX3232 led to profound reductions in inflammatory biomarkers, including up to a ~78% decrease in hsCRP and significant suppression of IL-6 levels.
Notably, these anti-inflammatory effects occurred independently of weight loss, underscoring a mechanism distinct from metabolic modulation.
When combined with semaglutide, VTX3232 demonstrated additive reductions in hsCRP, IL-6, lipoprotein(a), and fibrinogen, suggesting a complementary role alongside established cardiometabolic therapies. These findings reinforce the concept of targeting inflammation as an orthogonal axis of risk reduction.
However, current evidence remains limited to biomarker modulation, with no demonstrated impact on hard cardiovascular outcomes such as myocardial infarction, stroke, or cardiovascular mortality.
While mechanistically robust and clinically promising, the ultimate role of NLRP3 inhibition in atherosclerosis will depend on large-scale, event-driven trials.
Reference:
- Ventyx Biosciences. Phase 2a Study of VTX3232 in Cardiometabolic Risk (ACC 2026 Presentation);
- Molecular Metabolism (2025);
- Healio Cardiology News (2026).”
More posts featuring Ney Carter Borges on Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe LippiÖ‰ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question